PHASE Scientific Raises US$34 Million Series A Round to Advance Urine-Based Diagnostic Technology for Early Disease Detection - PR Newswire APAC
Summary
The funding round is led by a private equity fund managed by Value Partners Group (HKEX: 0806), one of Asias largest independent asset management firms, with significant backing from new healthcare-focused investors and continued support from existing global backers.Building on its patented PHASIFY urine concentration technologywhich captures over ten times more biomarkers than current industry gold standardsPHASE Scientific is the only player advancing a pipeline of urine-based liquid biopsy diagnostics. Building on this commercial success, PHASE Scientific has developed the worlds first urine-based HPV testa major breakthrough that has achieved significant clinical validation and global recognition. "The successful close of this landmark Series A financing validates the transformative potential of our technology and the growing global demand for accessible, accurate early disease detection," said Dr. Ricky Chiu, Founder, Chairman and CEO of PHASE Scientific. This advanced mechanism enables the concentration and purification of unlimited volumes of urine, dramatically increasing the sensitivity and accuracy of disease detection.This proprietary innovation uniquely positions PHASE Scientific as the only player in the urine-based liquid biopsy diagnostics field, with proven clinical performance for multi-cancer detection. With a non-invasive and painless approach, PHASIFY empowers convenient sample collection, unlocking new possibilities for early, accessible, and comprehensive disease screening and diagnosis.Value Partners, one of Asias leading independent asset management firms, seeks to offer world-class investment services and products.